Determining Elements of Anti-Fungal Immunity in BURN Patients (DEFI-BURN)

Assistance Publique - Hôpitaux de Paris

Status: Not yet enrolling

Conditions: Burn

Treatments: Other: Biological sampling

Study type: Observational

Funder types: Other

Identifiers

NCT06828458

APHP241672

Details and patient eligibility

About

Scientific justification Invasive fungal diseases (IFDs) pose a substantial threat, especially in immunocompromised patients, necessitating urgent research focus and therapeutic advancements. The IFI-BURN study, involving a cohort of patients with severe burn injury (n=276), revealed a significant IFD incidence of 31.6% and underscored their critical impact on morbidity and mortality. While fungi are present everywhere, for moulds within the environment and for yeasts within our microbiota, why certain patients develop IFDs and others do not, remains poorly understood. The answer most likely resides in the impact of the burn injury on the immune response, loss of skin barrier and particular predisposing immune phenotype of patients. The immune system is composed of both cellular and humoral components, but the latter is far less studied in antifungal immunity although they exert multiple antimicrobial mechanisms.

Enrollment: 327 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Burn patients

• Adult patients ≥ 18 years old
• Admission < 4 days following burn injury
• Total burn surface Area ≥ 15%
• Non opposition of the patient or his/her relatives to the research
• Affiliation to social security or any health insurance

Exclusion criteria

• Pregnancy
• Opposition of the patient or his/her relatives
• Decision not to resuscitate or to limit or stop active therapies

Trial design

327 participants in 1 patient group

Adult patients with burn injury

Treatment:

Other: Biological sampling